Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

33.10
+1.394.38%
Volume:851.69K
Turnover:27.91M
Market Cap:5.27B
PE:-11.04
High:33.15
Open:32.25
Low:32.01
Close:31.71
Loading ...

Wainzua (Eplontersen) Approved in the EU for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults With Stage 1 or Stage 2 Polyneuropathy

THOMSON REUTERS
·
10 Mar

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Business Wire
·
10 Mar

Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...

GuruFocus.com
·
27 Feb

Ionis to present at upcoming investor conferences

Business Wire
·
25 Feb

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

Zacks
·
24 Feb

Optimistic Future Outlook for Ionis Pharmaceuticals Driven by Robust Growth and Strategic Initiatives

TIPRANKS
·
23 Feb

Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James

TipRanks
·
21 Feb

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More

Zacks
·
21 Feb

Ionis Pharmaceuticals Inc : Bernstein Cuts Target Price to $43 From $51

THOMSON REUTERS
·
21 Feb

BRIEF-New Positive Donidalorsen Data To Be Presented At Aaaai/Wao Joint Congress

Reuters
·
20 Feb

New Positive Donidalorsen Data to Be Presented at Aaaai/Wao Joint Congress Highlight Sustained Hae Attack Rate Reduction and Disease Control

THOMSON REUTERS
·
20 Feb

Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
20 Feb

Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham

Dow Jones
·
20 Feb

Barclays Remains a Hold on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
20 Feb

Q4 2024 Ionis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Feb

Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

GuruFocus.com
·
20 Feb

Optimistic Buy Rating for Ionis Pharmaceuticals Driven by Promising Financial Outlook and Strategic Advancements

TIPRANKS
·
20 Feb

Ionis Pharmaceuticals price target lowered to $38 from $45 at Stifel

TIPRANKS
·
20 Feb

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

Benzinga
·
20 Feb

Ionis Pharmaceuticals trading resumes

TIPRANKS
·
19 Feb